Edwards Lifesciences (EW) Stock Forecast & Price Target

Compare

1,942 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EW Analyst Ratings

Moderate Buy

14 Buy

7 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Edwards

Lifesciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EW Stock 12 Month Forecast

Average Price Target

$97.11

▲(28.00% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Edwards Lifesciences in the last 3 months. The average price target is $97.11 with a high forecast of $110.00 and a low forecast of $86.00. The average price target represents a 28.00% change from the last price of $75.87.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"70":"$70","111":"$111","80.25":"$80.3","90.5":"$90.5","100.75":"$100.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":97.11111111111111,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$97.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$86.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[70,80.25,90.5,100.75,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,82.65,84.75384615384615,86.85769230769232,88.96153846153847,91.06538461538462,93.16923076923078,95.27307692307693,97.37692307692308,99.48076923076923,101.58461538461539,103.68846153846154,105.7923076923077,107.89615384615385,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,82.65,83.76239316239317,84.87478632478633,85.98717948717949,87.09957264957265,88.21196581196581,89.32435897435897,90.43675213675215,91.54914529914531,92.66153846153847,93.77393162393163,94.88632478632479,95.99871794871795,{"y":97.11111111111111,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,82.65,82.90769230769232,83.16538461538462,83.42307692307693,83.68076923076923,83.93846153846154,84.19615384615385,84.45384615384616,84.71153846153847,84.96923076923078,85.22692307692307,85.48461538461538,85.74230769230769,{"y":86,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":72.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.62,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.87,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.18,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.18,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.77,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.31,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.45,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.27,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.65,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$110.00

Average Price Target$97.11

Lowest Price Target$86.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Danielle Antalffy

UBS

$94→$90

Hold

18.62%

Upside

Reiterated

02/12/26

Edwards Lifesciences price target lowered to $90 from $94 at UBSEdwards Lifesciences price target lowered to $90 from $94 at UBS

Patrick Wood

Morgan Stanley

$86

Hold

13.35%

Upside

Reiterated

02/12/26

Edwards Lifesciences (EW) Receives a Hold from Morgan Stanley

Adam Maeder

Piper Sandler

$98→$100

Buy

31.80%

Upside

Reiterated

02/11/26

Piper Sandler Sticks to Its Buy Rating for Edwards Lifesciences (EW)

Richard Newitter

Truist Financial

$92→$89

Hold

17.31%

Upside

Reiterated

02/11/26

Truist Financial Keeps Their Hold Rating on Edwards Lifesciences (EW)

Suraj Kalia

Oppenheimer

Hold

―

Reiterated

02/11/26

David Rescott

Robert W. Baird

$90→$87

Hold

14.67%

Upside

Reiterated

02/11/26

Edwards Lifesciences price target lowered to $87 from $90 at BairdEdwards Lifesciences price target lowered to $87 from $90 at Baird

Josh Jennings

TD Cowen

$97

Buy

27.85%

Upside

Reiterated

02/11/26

TD Cowen Sticks to Their Buy Rating for Edwards Lifesciences (EW)

William Plovanic

Canaccord Genuity

$87

Hold

14.67%

Upside

Reiterated

02/11/26

Edwards Lifesciences (EW) Gets a Hold from Canaccord Genuity

Larry Biegelsen

Wells Fargo

$96→$100

Buy

31.80%

Upside

Reiterated

02/11/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Exelixis (NASDAQ: EXEL), Edwards Lifesciences (NYSE: EW) and Zimmer Biomet Holdings (NYSE: ZBH)

Brandon Vazquez

William Blair

Buy

―

Reiterated

02/11/26

Edwards Lifesciences: Capitalizing on TAVR Tailwinds, New Structural Heart Catalysts, and Attractive Valuation Upside

Rick Wise

Stifel Nicolaus

$110

Buy

44.98%

Upside

Reiterated

02/11/26

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW) and Disc Medicine (NASDAQ: IRON)

David Roman

Goldman Sachs

$108→$95

Buy

25.21%

Upside

Reiterated

02/11/26

Edwards Lifesciences price target lowered to $95 from $108 at Goldman SachsEdwards Lifesciences price target lowered to $95 from $108 at Goldman Sachs

Marie Thibault

BTIG

$103

Buy

35.76%

Upside

Reiterated

02/11/26

BTIG Reaffirms Their Buy Rating on Edwards Lifesciences (EW)

Joanne Wuensch

Citi

$101

Buy

33.12%

Upside

Reiterated

02/10/26

Buy Rating on Edwards Lifesciences Driven by Strong Core TAVR Momentum, Conservative 2026 Guidance, and Attractive Risk‑Reward Profile

Travis Steed

Bank of America Securities

$103

Buy

35.76%

Upside

Reiterated

02/10/26

Edwards Lifesciences: Sustained TAVR Momentum, Margin Upside, and New LAAC Growth Support Buy Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Danielle Antalffy

UBS

$94→$90

Hold

18.62%

Upside

Reiterated

02/12/26

Edwards Lifesciences price target lowered to $90 from $94 at UBSEdwards Lifesciences price target lowered to $90 from $94 at UBS

Patrick Wood

Morgan Stanley

$86

Hold

13.35%

Upside

Reiterated

02/12/26

Edwards Lifesciences (EW) Receives a Hold from Morgan Stanley

Adam Maeder

Piper Sandler

$98→$100

Buy

31.80%

Upside

Reiterated

02/11/26

Piper Sandler Sticks to Its Buy Rating for Edwards Lifesciences (EW)

Richard Newitter

Truist Financial

$92→$89

Hold

17.31%

Upside

Reiterated

02/11/26

Truist Financial Keeps Their Hold Rating on Edwards Lifesciences (EW)

Suraj Kalia

Oppenheimer

Hold

―

Reiterated

02/11/26

David Rescott

Robert W. Baird

$90→$87

Hold

14.67%

Upside

Reiterated

02/11/26

Edwards Lifesciences price target lowered to $87 from $90 at BairdEdwards Lifesciences price target lowered to $87 from $90 at Baird

Josh Jennings

TD Cowen

$97

Buy

27.85%

Upside

Reiterated

02/11/26

TD Cowen Sticks to Their Buy Rating for Edwards Lifesciences (EW)

William Plovanic

Canaccord Genuity

$87

Hold

14.67%

Upside

Reiterated

02/11/26

Edwards Lifesciences (EW) Gets a Hold from Canaccord Genuity

Larry Biegelsen

Wells Fargo

$96→$100

Buy

31.80%

Upside

Reiterated

02/11/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Exelixis (NASDAQ: EXEL), Edwards Lifesciences (NYSE: EW) and Zimmer Biomet Holdings (NYSE: ZBH)

Brandon Vazquez

William Blair

Buy

―

Reiterated

02/11/26

Edwards Lifesciences: Capitalizing on TAVR Tailwinds, New Structural Heart Catalysts, and Attractive Valuation Upside

Rick Wise

Stifel Nicolaus

$110

Buy

44.98%

Upside

Reiterated

02/11/26

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW) and Disc Medicine (NASDAQ: IRON)

David Roman

Goldman Sachs

$108→$95

Buy

25.21%

Upside

Reiterated

02/11/26

Edwards Lifesciences price target lowered to $95 from $108 at Goldman SachsEdwards Lifesciences price target lowered to $95 from $108 at Goldman Sachs

Marie Thibault

BTIG

$103

Buy

35.76%

Upside

Reiterated

02/11/26

BTIG Reaffirms Their Buy Rating on Edwards Lifesciences (EW)

Joanne Wuensch

Citi

$101

Buy

33.12%

Upside

Reiterated

02/10/26

Buy Rating on Edwards Lifesciences Driven by Strong Core TAVR Momentum, Conservative 2026 Guidance, and Attractive Risk‑Reward Profile

Travis Steed

Bank of America Securities

$103

Buy

35.76%

Upside

Reiterated

02/10/26

Edwards Lifesciences: Sustained TAVR Momentum, Margin Upside, and New LAAC Growth Support Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Edwards Lifesciences

3 Months

xxx

Success Rate

15/24 ratings generated profit

Average Return

+2.19%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +2.19% per trade.

1 Year

Jayson BedfordRaymond James

Success Rate

17/25 ratings generated profit

Average Return

+11.24%

a rating ―

Copying Jayson Bedford's trades and holding each position for 1 Year would result in 68.00% of your transactions generating a profit, with an average return of +11.24% per trade.

2 Years

xxx

Success Rate

15/25 ratings generated profit

Average Return

+16.26%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +16.26% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EW Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EW has received 47 Buy Ratings, 18 Hold Ratings, and 0 Sell Ratings. EW average Analyst price target in the past 3 months is 97.11.

Each month's total comprises the sum of three months' worth of ratings.

EW Financial Forecast

EW Earnings Forecast

Next quarter’s earnings estimate for EW is $0.73 with a range of $0.70 to $0.75. The previous quarter’s EPS was $0.58. EW beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year EW has Performed in-line its overall industry.

EW Sales Forecast

Next quarter’s sales forecast for EW is $1.60B with a range of $1.57B to $1.63B. The previous quarter’s sales results were $1.57B. EW beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year EW has Performed in-line its overall industry.

EW Stock Forecast FAQ

What is EW’s average 12-month price target, according to analysts?

Based on analyst ratings, Edwards Lifesciences’s 12-month average price target is 97.11.

What is EW’s upside potential, based on the analysts’ average price target?

Edwards Lifesciences has 28.00% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EW a Buy, Sell or Hold?

Edwards Lifesciences has a consensus rating of Moderate Buy which is based on 14 buy ratings, 7 hold ratings and 0 sell ratings.

What is Edwards Lifesciences’s price target?

The average price target for Edwards Lifesciences is 97.11. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $110.00 ,the lowest forecast is $86.00. The average price target represents 28.00% Increase from the current price of $75.87.

What do analysts say about Edwards Lifesciences?

Edwards Lifesciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of EW?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Edwards Lifesciences (EW) Stock Forecast & Price Target

EW Analyst Ratings

EW Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Edwards Lifesciences

EW Analyst Recommendation Trends

EW Financial Forecast

EW Earnings Forecast

EW Sales Forecast

EW Stock Forecast FAQ

Detailed List of Analyst Forecasts